Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Long-Term Investments (2022 - 2025)

Indivior Pharmaceuticals (INDV) has 4 years of Long-Term Investments data on record, last reported at $28.0 million in Q4 2025.

  • For Q4 2025, Long-Term Investments rose 3.7% year-over-year to $28.0 million; the TTM value through Dec 2025 reached $28.0 million, up 3.7%, while the annual FY2025 figure was $28.0 million, 3.7% up from the prior year.
  • Long-Term Investments reached $28.0 million in Q4 2025 per INDV's latest filing, roughly flat from $28.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $98.0 million in Q4 2022 and bottomed at $27.0 million in Q4 2024.
  • Average Long-Term Investments over 4 years is $39.4 million, with a median of $28.0 million recorded in 2025.
  • Peak YoY movement for Long-Term Investments: crashed 58.16% in 2023, then increased 3.7% in 2025.
  • A 4-year view of Long-Term Investments shows it stood at $98.0 million in 2022, then plummeted by 58.16% to $41.0 million in 2023, then tumbled by 34.15% to $27.0 million in 2024, then rose by 3.7% to $28.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $28.0 million in Q4 2025, $28.0 million in Q3 2025, and $27.0 million in Q2 2025.